Radiotherapy Fails to Improve Survival in Limb Liposarcoma, Study Finds

For decades, patients diagnosed with liposarcoma of the limbs have often been offered a familiar package of care: surgery to remove the tumor, followed by weeks of radiation therapy intended to keep the cancer from coming back. The logic seemed sound. Liposarcomas frequently sit dangerously close to major nerves and blood vessels, making wide surgical margins difficult to achieve, and radiation has long been used to mop up any malignant cells left behind. But a new retrospective study from a major Chinese sarcoma center is now challenging that assumption, and its findings are already sparking debate among orthopedic oncologists about who truly benefits from adjuvant radiotherapy.

The research, conducted at the Department of Bone and Soft Tissue Oncology of the Second Affiliated Hospital of Zhejiang University School of Medicine, followed 153 patients with primary limb liposarcoma treated between January 2015 and April 2023. All patients underwent limb-sparing surgical resection, and decisions about additional treatment were made by a multidisciplinary tumor board. The researchers then divided the cohort into two groups: those who received adjuvant radiotherapy and those who did not. Their central question was deceptively simple—did the radiation actually improve survival or reduce recurrence?

Answering that question in oncology is harder than it sounds, because patients are not randomly assigned to treatment. Radiation is typically offered to those with the highest risk of recurrence: deep tumors, high-grade histology, or close surgical margins. That means the radiotherapy group starts out sicker, and any naive comparison between the groups would be hopelessly biased. To address this, the team employed propensity score matching, a statistical technique that pairs patients from each group based on eleven baseline characteristics, including age, sex, tumor grade, tumor size, tumor location, tumor type, surgical margin status, involvement of vascular and nerve bundles, use of chemotherapy, and any history of recurrence following surgery at another institution.

The results were striking. Before matching, the five-year overall survival rate was 88.8 percent in the non-radiotherapy group compared with 71.1 percent in the radiotherapy group, a difference that narrowly missed statistical significance. After propensity score matching, the gap persisted—85.2 percent versus 71.1 percent—but was no longer statistically meaningful. Recurrence-free survival told a similar story. Before matching, the non-irradiated patients fared dramatically better, with a five-year recurrence-free survival of 75.6 percent against just 41.8 percent in the irradiated group. Yet after the covariates were balanced, that apparent advantage shrank to 64.8 percent versus 41.8 percent, a difference that no longer reached significance. In total, the study recorded 16 deaths and 24 recurrences among patients who did not receive radiation, and 9 deaths and 12 recurrences among those who did.

Perhaps the most provocative finding emerged from the subgroup analysis of myxoid liposarcoma, a distinct molecular subtype that accounts for roughly 30 percent of all liposarcomas. Myxoid tumors carry a characteristic genetic signature—a translocation between chromosomes 12 and 16 that produces an abnormal FUS-DDIT3 fusion protein—and this fusion is thought to confer increased radiosensitivity. In theory, myxoid liposarcoma should be the subtype most likely to benefit from radiation. Instead, after propensity score matching, the irradiated myxoid patients showed significantly worse recurrence-free survival: 48.4 percent versus 86.5 percent in the non-irradiated group. Overall survival, however, remained comparable between the two groups in this subgroup.

The authors are careful to interpret this counterintuitive result with caution. They note that residual confounders may persist even after matching, and that the retrospective design meant important variables influencing the decision to irradiate—such as precise tumor depth and detailed margin characteristics—were not captured in the dataset. Propensity score matching also shrinks the effective sample size and can redistribute risk in ways that exaggerate differences. In other words, the worse recurrence outcomes among irradiated myxoid patients may reflect the fact that these were inherently higher-risk tumors, not that radiation itself caused harm. Still, the finding undercuts the standard rationale for treating myxoid liposarcoma as a radiosensitive disease, and it will likely prompt closer scrutiny of how this subtype is managed in clinics worldwide.

Beyond the radiotherapy question, the multivariate Cox regression analysis identified older age as the one factor that independently predicted death after matching, with each additional year of age raising the hazard of mortality by about 6 percent. This aligns with a broader body of literature showing worse outcomes for older liposarcoma patients, possibly reflecting differences in tumor biology, comorbidities, and treatment tolerance. Before matching, the analysis also flagged adjuvant chemotherapy as a dramatic risk factor for mortality, with a hazard ratio of 9.18—but the researchers urge readers not to overinterpret this. Chemotherapy, a regimen of doxorubicin and ifosfamide delivered over four to six cycles, was reserved for patients with large, high-grade tumors, meaning the association almost certainly reflects confounding by indication rather than a toxic effect of the drugs themselves. A previous analysis of the SEER database reached a similar conclusion.

The technical details of the treatment protocols matter for understanding the study’s scope. Radiotherapy was delivered using modern techniques—either intensity-modulated radiotherapy or three-dimensional conformal radiotherapy—with total doses of 50 to 60 Gray administered in daily 2 Gray fractions over five to six weeks. These are standard doses and delivery schedules for soft tissue sarcoma, so the results cannot be dismissed as an artifact of outdated radiation practice. Follow-up was rigorous, with clinical and imaging assessments at 1, 3, 6, and 12 months after surgery and every six months thereafter, using ultrasound or magnetic resonance imaging to detect local recurrence and chest computed tomography to screen for distant metastasis, with histological confirmation whenever feasible.

What does this mean for patients? The study’s conclusion is not that radiation is useless for everyone. The authors explicitly state that radiotherapy may still be appropriate for certain high-risk individuals, and the retrospective, single-center design with a modest sample size—particularly in the subgroup analyses—limits the statistical power of the findings. Variations in institutional practice could also have influenced the results even after matching. But the study does suggest that routine adjuvant radiotherapy for limb liposarcoma deserves skepticism, and that individualized surgical strategy, aimed at achieving wide negative margins whenever anatomically possible, should take priority over reflexive irradiation. The only independent risk factor for recurrence identified in the analysis was a history of prior recurrence following surgery at an outside institution, which underscores how much the quality of the initial operation matters.

Liposarcoma is the most common soft tissue sarcoma of adulthood, representing roughly 15 to 20 percent of cases, and it spans a biological spectrum from the indolent, low-metastatic-potential well-differentiated form to the aggressive pleomorphic and dedifferentiated subtypes. Reported five-year overall survival ranges widely, from 57 to 93 percent, depending on histology and clinical characteristics. Because these tumors so often wrap around the neurovascular bundles of the thigh and upper arm, the surgical dilemma at the heart of this study is one that sarcoma surgeons confront every week. As larger, ideally multicenter and prospective studies are mounted to settle the question definitively, this propensity-matched analysis adds a compelling data point to a growing argument that in limb liposarcoma, the scalpel—not the radiation beam—remains the decisive weapon.

Subject of Research: Adjuvant radiotherapy outcomes in limb liposarcoma assessed by propensity score matching

Article Title: Does radiotherapy improve the prognosis of limb liposarcoma? A retrospective study based on propensity score matching

Article References: Wang, K., Zhang, J., Li, B., Mou, H., Yang, Z., Lin, N., Ye, Z., & Qu, H. (2026). Does radiotherapy improve the prognosis of limb liposarcoma? A retrospective study based on propensity score matching. Holistic Integrative Oncology, 5(1), Article 26. https://doi.org/10.1007/s44178-026-00242-3

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00242-3

Keywords: liposarcoma, radiotherapy, soft tissue sarcoma, propensity score matching, myxoid liposarcoma, recurrence-free survival, overall survival, prognostic factors, surgical margins, adjuvant therapy, oncology, retrospective study